Anteris Technologies presented 30-day clinical outcomes for the DurAVR ® THV in 100 severe aortic stenosis patients with small aortic annuli.
Results showed favorable hemodynamic profiles, no valve-related mortality, and significant reduction in prosthesis-patient mismatch.
The presentation highlighted the success rates and potential implications for the PARADIGM Trial.
Favorable Hemodynamic Profile
DurAVR ® THV showed large effective orifice areas and low mean pressure gradients, indicating positive clinical outcomes at 30 days.
Reduced Prosthesis-Patient Mismatch
Results demonstrated a significant decrease in prosthesis-patient mismatch, enhancing the safety and success of the device.
Technical and Device Success
The technical success rate of 100% in the last 50 patient implants underscores the effectiveness of the DurAVR ® THV technology.
Clinical Relevance
Achieving 97% freedom from moderate or severe prosthesis-patient mismatch is crucial for small annuli patients, reducing risks associated with valve failure.
- The presented data at the PCR London Valves conference showcased promising 30-day outcomes with minimal complications and high success rates.
- The positive hemodynamic profiles and low incidence of prosthesis-patient mismatch suggest the potential for DurAVR ® THV to address critical challenges in aortic stenosis treatment.
The consistent clinical profile and positive outcomes of the DurAVR ® THV in small annuli patients reinforce its potential as a life-saving technology. The upcoming PARADIGM Trial is expected to further validate its efficacy in treating severe aortic stenosis.